Greenland Mines Secures Australian Patent for Klotho Gene Therapy Platform Targeting ALS

Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.

The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders. The patent grant is a significant milestone for Greenland Mines’ biotech division, which is focused on advancing novel therapies for devastating diseases. The Klotho protein has been studied for its potential anti-aging and neuroprotective effects, and the company believes its gene therapy approach could offer a new treatment paradigm for patients with ALS, a progressive neurodegenerative disease that currently has limited therapeutic options.

Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

The patent grant in Australia adds to the company’s intellectual property portfolio and provides legal protection for its Klotho gene therapy platform in a key jurisdiction. This development underscores the company’s commitment to advancing its biotech pipeline while also pursuing its mining operations. The full press release is available at https://nnw.fm/PVbbH.

For more information about Greenland Mines, visit the company’s newsroom at https://nnw.fm/GRML.